LYVE1 Rabbit anti-Human, Polyclonal, Proteintech

Description

• LYVE1 has been identified as a major receptor for HA (extracellular matrix glycosaminoglycan hyaluro) on the lymph vessel wall
• The deduced amino acid sequence of LYVE1 predicts a 322-residue type I integral membrane polypeptide 41% similar to the CD44 HA receptor with a 212-residue extracellular domain containing a single Link module, the prototypic HA binding domain of the Link protein superfamily
• Like CD44, the LYVE1 molecule binds both soluble and immobilized HA
• However, unlike CD44, the LYVE1 molecule colocalizes with HA on the luminal face of the lymph vessel wall and is completely absent from blood vessels
• Hence, LYVE1 is the first lymph-specific HA receptor to be characterized and is a uniquely powerful marker for lymph vessels themselves
• LYVE1 is a type I integral membrane glycoprotein
• LYVE-1 is expressed primarily on lymphatic vessel endothelium and is likely to be involved in regulating the traffic of leucocytes and tumor cells to lymph nodes
• The lymphatic vasculature forms a second circulatory system that drains extracellular fluid from the tissues and provides an exclusive environment in which immune cells can encounter and respond to foreign antigen
• A number of molecules have been identified as markers for lymphatic endothelium which include LYVE1, PALE, VEGFR3, and podoplanin
• Diseases associated with LYVE1 dysfunction includes Complete Androgen Insensitivity Syndrome.